OtherOpen
6550--Notice of Intent to Sole-Source T-SPOT.TB® Reagents and Kits
VETERANS AFFAIRS, DEPARTMENT OF › 242-NETWORK CONTRACT OFFICE 02 (36C242)
Response deadlineOct 16, 2026 4:00 PM EDT · 10 days left
View official notice on SAM.gov ↗ (opens in a new tab)
Verify before acting. Users must verify deadlines, amendments, attachments, eligibility, and submission requirements on the official SAM.gov notice.
Read the Data Disclaimer.
Key decision factors
- Response deadline
- Oct 16, 2026 4:00 PM EDT · 10 days left
- Posted
- Oct 2, 2026 12:00 AM EDT
- Notice type
- Special Notice
- Set-aside
- Not provided or not applicable
- PSC
- 6550 — In Vitro Diagnostic Substances, Reagents, Test Kits and Sets
- Place of performance
- Not specified
- Current status
- Open
Notice details
- Official status
- Open
- Normalized group
- Other
- Notice ID
- d50ba2f2eb5a4791a7ce9e599cc69cbf
- Solicitation number
- 36C24227Q0036
Description
Displayed as sanitized plain text from SAM.gov. Retrieved Oct 5, 2026 12:11 AM EDT.
This notice is being published in accordance with Revolutionary FAR Overhaul Federal Acquisition Regulation (RFO FAR) Subpart 5.101 requiring dissemination of information for proposed contract actions. The Department of Veterans Affairs, Network Contracting Office (NCO) 2, hereby provides notice of its intent to award a sole source, firm fixed price contract to Euroimmun US Incorporated, the sole authorized U.S. distributor of T SPOT.TB® reagents and associated kits manufactured by Oxford Immunotec. These reagents are required for tuberculosis testing at VA Western New York Healthcare System (VAWNYHS) Buffalo VA Medical Center (VAMC). This determination is made in accordance with RFO FAR 12.201-1, Only one responsible source and no other supplies or services will satisfy agency requirements. The T SPOT.TB® assay is a patented IGRA platform, and its reagents including the antigen panels, controls, and AIM V media are proprietary and FDA cleared only for use with the OEM platform. Oxford Immunotec holds the exclusive patent rights, and Euroimmun US Incorporated is the only supplier legally authorized to provide these FDA approved reagents for federal healthcare facilities. No other vendor can supply reagents that meet FDA, CLIA, CAP, and Joint Commission requirements. This notice is not a request for competitive quotes. However, interested parties may identify their interest and capability to respond to this requirement by submitting a: Capability Statement (1 page maximum) Company Name UEI Number Socioeconomic Status Proof of authorization to provide the OEM reagents Responses must be received no later than 4:00 PM EST on October 16, 2026 to Myra.Green2@va.gov A determination not to compete this proposed action is solely within the discretion of the Government. Information received will only be considered for determining whether to conduct a competitive procurement in the future. Prospective contractors must be registered in SAM.gov to be eligible for award.
Personalized relevance
Would this fit your company?
Create company profile information with a free account to see a deterministic, explainable relevance score. Matching does not determine eligibility or win probability.
Create Free Account
Pursuit risk (separate from your match score)
Strong pursuit warning
This notice contains language indicating a sole-source or otherwise restricted procurement. Review the cited evidence before investing time in a response.
Detected in
- Notice title“6550--Notice of Intent to Sole-Source T-SPOT.TB® Reagents and Kits”
- Description“plies or services will satisfy agency requirements. The T SPOT.TB® assay is a patented IGRA platform, and its reagents including the antigen panels, controls, and AIM V media are proprietary and FDA cleared only for use”
Pursuit risk is evaluated separately from your match score above and never changes it. This is not a legal or eligibility determination — verify against the official SAM.gov notice and attachments.